Morgan Stanley lowered the firm’s price target on Dentsply Sirona (XRAY) to $23 from $30 and keeps an Overweight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Shareholder Alert for Dentsply Sirona, Inc. (NASDAQ:XRAY)
- GE Vernova initiated, Merck upgraded: Wall Street’s top analyst calls
- Dentsply Sirona initiated with a Neutral at Mizuho
- Patterson Companies initiated with a Neutral at Mizuho
- Dentsply Sirona Inc. Class Action: Levi & Korsinsky LLP Reminds Dentsply Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 27, 2025 – XRAY
Questions or Comments about the article? Write to editor@tipranks.com